Physician profile
Carley Mitchell
NPI 1013544048
$865.99
in general payments reported to CMS, 2019-2025
15 companies · $544 in 2025
The $544 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $322 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $766.04 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $141.10 | 2024-2025 | |
| Genzyme Corporation | $115.81 | 2024-2025 | |
| Seagen INC. | $99.95 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $77.76 | 2024-2025 | Imfinzi |
| Novartis Pharmaceuticals Corporation | $73.84 | 2024 | |
| Daiichi Sankyo INC. | $66.07 | 2024-2025 | Enhertu |
| Emd Serono, INC. | $47.65 | 2025 | |
| Blueprint Medicines Corporation | $42.06 | 2024 | Ayvakit |
| Merck Sharp & Dohme LLC | $40.77 | 2024-2025 | Keytruda |
| Abbvie INC. | $36.09 | 2025 | |
| Exelixis INC. | $30.02 | 2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $28.26 | 2025 | Fruzaqla |
| Lilly USA, LLC | $26.60 | 2025 | Verzenio, Jaypirca |
| Beone Medicines USA, INC. | $20.03 | 2025 | Tevimbra |
| Gilead Sciences, INC. | $19.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carley Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.